Asset Details
Do you wish to reserve the book?
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Do you wish to request the book?
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
2016
Overview
The addition of olanzapine to a neurokinin receptor blocker, a serotonin receptor blocker, and dexamethasone markedly improved the control of nausea and vomiting in previously untreated patients receiving highly emetogenic chemotherapy.
Chemotherapy-induced nausea and vomiting are associated with a significant deterioration in quality of life and are perceived by patients as major adverse effects of cancer treatment.
1
The use of 5-hydroxytryptamine type 3 (5-HT
3
) receptor antagonists,
2
dexamethasone,
2
and neurokinin-1 (NK
1
) receptor antagonists
3
–
9
has significantly improved the control of this troublesome side effect. International guidelines
10
–
12
recommend combinations of these agents to prevent chemotherapy-induced nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy. Nonetheless, nausea remains a major problem for many patients.
1
,
2
Olanzapine is approved by the Food and Drug Administration (FDA) as an . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antiemetics - adverse effects
/ Antiemetics - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Benzodiazepines - adverse effects
/ Benzodiazepines - therapeutic use
/ Dexamethasone - therapeutic use
/ Diabetes
/ Female
/ Humans
/ Male
/ Morpholines - therapeutic use
/ Nausea
/ Nausea - prevention & control
/ Vomiting
